Alignment Healthcare Inc (ALHC) concluded trading on Wednesday at a closing price of $15.44, with 4.62 million shares of worth about $71.33 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 35.56% during that period and on June 11, 2025 the price saw a gain of about 5.39%. Currently the company’s common shares owned by public are about 197.67M shares, out of which, 130.88M shares are available for trading.
Stock saw a price change of 0.78% in past 5 days and over the past one month there was a price change of 3.49%. Year-to-date (YTD), ALHC shares are showing a performance of 37.24% which increased to 85.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.05 but also hit the highest price of $21.06 during that period. The average intraday trading volume for Alignment Healthcare Inc shares is 3.36 million. The stock is currently trading 1.93% above its 20-day simple moving average (SMA20), while that difference is down -6.71% for SMA50 and it goes to 12.64% higher than SMA200.
Alignment Healthcare Inc (NASDAQ: ALHC) currently have 197.67M outstanding shares and institutions hold larger chunk of about 59.24% of that.
The stock has a current market capitalization of $3.05B and its 3Y-monthly beta is at 1.22. It has posted earnings per share of -$0.47 in the same period. It has a debt-to-equity ratio of 3.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALHC, volatility over the week remained 3.68% while standing at 3.24% over the month.
Stock’s fiscal year EPS is expected to rise by 48.46% while it is estimated to increase by 73.90% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stephens on December 03, 2024 offering an Overweight rating for the stock and assigned a target price range of between $13 and $17 to it. On May 30, 2024, BofA Securities Upgrade their recommendations, while on May 30, 2024, Robert W. Baird Initiated their ratings for the stock with a price target of $10. Stock get an Overweight rating from Piper Sandler on May 08, 2024.
